Printer Friendly
The Free Library
4,536,229 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Technology Management & Funding announces licensing agreement between Boron Biologicals and Duke University; Nucleic acid technology provides significant breakthroughs for DNA diagnostics and therapeutics, now available for licensing to worldwide market segments.


PRINCETON, N.J.--(BUSINESS WIRE)--Aug. 8, 1995--Technology Management & Funding, L.P. (TMF TMF - 3-Methylfentanyl
TMF - Table Mountain Facility (JPL)
TMF - Tele-Manufacturing Facility
TMF - Telemanagement Forum
TMF - Terminated Merchant File (credit card systems)
TMF - Texas Medical Foundation
TMF - Texture Masking Function
TMF - The Media Fund
TMF - The Motley Fool
TMF - The Music Factory (TV)
TMF - Theater Manpower Force
TMF - Thermo-Mechanical Fatigue
TMF - Thin Metal Film
TMF - Thrust Management Function
), a firm providing unique commercialization and funding solutions to emerging high-technology companies, has announced a licensing agreement between Boron Biologicals Inc. (BBI BBI - B'nai Brith International
BBI - Balanced Bridge Interferometer modulator (fiber optics)
BBI - Band Busses, Inc.
BBI - Beanie Baby-Itis
BBI - Berlin Brandenburg International (Airport)
BBI - Best Brains Inc.
BBI - Bhubaneswar, India - Bhubaneswar (Airport Code)
BBI - Bi-Directional Backplane Interface (Nortel)
BBI - Biker Babes' Idol
BBI - Bio-Behavioral Institute
BBI - Blockbuster Inc.
), one of its portfolio companies, and Duke University.

The agreement covers several patents, issued and pending, regarding the synthesis and application of boronated nucleic acids. The family of boronated compounds related to DNA and RNA are the focus of BBI's collaboration with Duke University.

BBI has developed novel ways of creating molecules that are similar to those that occur in nature but have at least one boron atom inserted at key locations. These boronated biomolecules biomolecule /bio·mol·e·cule/ (-mol´e-kul) a molecule produced by living cells, e.g., a protein, carbohydrate, lipid, or nucleic acid. have unique characteristics which lead to the development of significantly improved DNA diagnostics and therapeutics. In addition, the company's approach represents a unique tool for researchers attempting to find the correct lock and key molecules using rational drug design.

"Boron Biologicals Inc. is the only company in the world focused on the boronation of biologically active compounds," said Dr. Karen J. Giroux, vice president of TMF. "The collaborative efforts of BBI and Duke University have resulted in significant breakthroughs with nucleic acids. These compounds hold exciting possibilities for significant improvements in therapeutics and diagnostics."

Boronated strands of DNA or RNA are strongly resistant to enzyme degradation by nucleases nuclease /nu·cle·ase/ (noo´kle-as) any of a group of enzymes that split nucleic acids into nucleotides
cyclic nucleotides  those in which the phosphate group bonds to two atoms of the sugar forming a ring, as in cyclic AMP and cyclic GMP, which act as intracellular second messengers.


nu·cle·o·tide (n
 and other products.

nu·cle·ase (n
 present throughout the body. They also have the potential of moving more easily through cell membranes. These breakthroughs offer great promise as an enabling technology in the development of antisense and gene therapies to combat genetic diseases.

Boronated nucleotides also form the basis of the Shaw-Porter sequencing technique, a new simplified and automated PCR sequencing method which can be used for identification of gene sequences. The basis of this technology resides in the ease of incorporation of boronated nucleotides into nucleic acid molecules by DNA polymerase DNA polymerase /DNA po·lym·er·ase/ (pah-lim´er-as) any of various enzymes catalyzing the template-directed incorporation of deoxyribonucleotides into a DNA chain, particularly one using a DNA template., coupled with the nuclease resistance provided by these modified nucleotides.

Another valuable use of BBI's nucleic acid technology is a simplified method for detecting boronated compounds. Incorporation of these compounds will allow identification "sites" where the boronated molecules attach to complimentary naturally occurring DNA or RNA. The greatest advantages to this detection method, over all known competing technologies, are its speed, simplicity, low cost, accuracy and quantifiability.

"Boronated nucleotides have presented BBI with a near-term commercial opportunity in the exploding DNA sequencing and diagnostics markets," explained Dr. Bernard F. Spielvogel, chairman of BBI. "Novel boronated molecules also have intriguing innate biological activities which add a new dimension to rational drug design."

TMF specializes in establishing partnering relationships between the technology-based companies in its portfolio and corporations that can provide funding and market access to these innovative technologies. The commercialization plan that TMF developed with BBI will initially focus on partnering activities within the nucleic acid diagnostic and therapeutic sectors, including DNA sequencing and detection, antisense, and gene therapy. Currently, TMF is in discussions with a select group of pharmaceutical and biomedical companies who are interested in pursuing collaborations for these areas.

The projected total market for DNA probes by 1997 is $686 million. The antisense and gene therapy world-wide markets are estimated to have multi-billion dollar potentials. The markets for therapeutics derived through rational drug design are both broad and substantial.

Boron Biologicals Inc., based in Raleigh, North Carolina, is a research and development company. BBI has pioneered the development of "organic" boron biomolecules which, while similar to natural carbon-based biomolecules, exhibit unique properties of their own that form the basis for an untapped, commercially valuable technology. New chemistries with pharmaceutical, diagnostic and other life-science applications are derived from BBI's technology. Biomedical applications of BBI's technology include DNA-based diagnostics and therapeutics, diagnostic imaging, and Boron Neutron Capture Therapy boron neutron capture therapy
n.
A treatment for cancers, especially virulent ones of the brain, in which a person who has been injected with a boron compound that concentrates in cancerous cells is exposed to neutron irradiation causing the boron compound to emit alpha particles that destroy the cancer cells.
. Further, in preclinical studies, BBI's biomolecules have demonstrated a high level of pharmacological activity against cancer, osteoporosis, viral infections, high cholesterol and inflammation.

Technology Management & Funding, L.P., based in Princeton, accelerates the process of building equity value in emerging high-technology companies, while minimizing investment risk. TMF bridges the gap between technological innovation and commercialization by establishing partnerships between small technology companies and major corporations. TMF currently has over 37 companies in its portfolio that have developed breakthrough technologies ranging from industrial products and biotechnology to software and telecommunications.

CONTACT: Technology Management & Funding, Princeton

Cristal Downing, 609/921-2001

cristaldowning@tmflp.com
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 8, 1995
Words:713
Previous Article:Macmillan Computer Publishing USA Forms West Coast Technology Group; QUE New Technologies Group to Broaden Publishing and Software Products for...
Next Article:WESTON opens environmental services office to serve Eastern Washington State.
Topics:



Related Articles
Organon Teknika further strengthens its NASBA nucleic acid amplification technology base.
Gen-Probe strengthens hold on amplification technology with two new patents.
Ixsys Receives Expanded US Patent Coverage For RNA, DNA Libraries.
PE Biosystems and Boston Probes, Inc. Enter Into Cross-license to Commercialize PNA Probe Technology; PE Biosystems Purchases Minority Investment in...
Applied Biosystems and Amersham plc Settle Sequencing Patent Litigation.
BAYER TO ACQUIRE VISIBLE GENETICS FOR $61.4 MILLION IN CASH.
Transgenomic Inc. and Geron Corporation Sign Licensing Agreement Covering Novel Class of Synthetic Nucleic Acids.
DXS AND SANGTEC SIGN SCORPIONS TECHNOLOGY LICENSE PACT.
Applied Biosystems Announces First Licensee Under Expanded PCR Licensing Program; Key Patents Covering Real-Time PCR Now Included in Program.
Copernicus Demonstrates Ability of Its Non-Viral Delivery System to Efficiently Transfer Large Sizes of Nucleic Acid into Lung Cells.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles